Full-Time
Phlebotomist
LabCorp
10,001+ employees
Global life sciences R&D services
No salary listed
Wichita, KS, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to LabCorp
See people who can refer or advise you
- A high school diploma or equivalent is required.
- At least three months of phlebotomy experience is required.
- Perform blood collections by venipuncture and capillary techniques for all age groups.
- Collect specimens for drug screens, paternity tests, and alcohol tests.
- Enter patient information accurately and in a timely manner.
- Process billing information and collect payments when required.
- Prepare collected specimens for testing and analysis.
- Maintain patient and specimen information logs.
- Provide customer service to all patients.
- Perform administrative and clerical duties as necessary.
- Travel to additional sites when needed.
- Phlebotomy certification, a completed training program, or one year or more of experience as a phlebotomist is preferred.
- A phlebotomy certification or completed training program used in lieu of work experience must come from an accredited agency.
- A proven track record in providing exceptional customer service is preferred.
- Strong written and verbal communication skills are preferred.
- The ability to work independently or in a team environment is preferred.
- Comfort working under minimal supervision is preferred.
- Reliable transportation and a clean driving record are preferred if applicable.
- Flexibility to work overtime as needed is preferred.
- The ability to pass a standardized color blindness test is preferred.
Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.
Company Size
10,001+
Company Stage
IPO
Headquarters
Burlington, Vermont
Founded
1976
Get referred to LabCorp
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 5.8% to $3.73 billion, with adjusted EPS up 14.9%.
- Labcorp raised 2026 revenue guidance to 5.4%-6.3% and EPS to $18.10-$18.55.
- Specialty testing, oncology, and biopharma services all delivered double-digit or faster-than-routine growth in H1 2026.
What critics are saying
- Jan. 2026 Bedford closure cut 94 jobs, signaling continuing restructuring across early development labs.
- July 2026 DOJ settlement forced Labcorp to pay $14.5 million over unnecessary urine drug tests.
- Diagnostics reimbursement pressure and Quest's faster routine testing execution can erase specialty growth gains by 2027.
What makes LabCorp unique
- Aug. 10, 2026 FDA approval of PGDx elio CDx expands Labcorp's oncology diagnostics moat.
- Labcorp combines 2,200 patient service centers with on-demand genetics and licensed counselors.
- July 2026 PTEN and melanoma launches deepen Labcorp's kit-based companion diagnostic pipeline.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Tuition Reimbursement
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Labcorp Holdings is showing improved growth in the second half of 2026, with stronger revenue, wider margins, and raised full-year guidance. Specialty testing in oncology, women's health, and autoimmune disease delivered double-digit revenue growth in the first half. The company's 2026 revenues are expected to grow 5.6% year over year. Second-quarter adjusted operating margin expanded 70 basis points year over year to 15.8%. Diagnostics margin rose 50 basis points to 18%, whilst Biopharma Laboratory Services margin increased 130 basis points to 17%. The gains came from organic growth, operating efficiencies, and technology initiatives including automation and artificial intelligence. However, the stock now trades at 16.7 times forward 12-month earnings, above both its five-year median of 14.4 times and its industry multiple of 16.2 times, leaving limited room for execution errors.
Labcorp announced that the US Food and Drug Administration has approved its PGDx elio tissue complete CDx as a companion diagnostic for advanced melanoma patients. The test identifies patients with certain BRAF variants who may benefit from FDA-approved BRAF inhibitors and BRAF/MEK inhibitor combination therapies. Melanoma is the deadliest form of skin cancer, with a five-year survival rate of just 16% for stage IV patients. Targeted therapies offer an important treatment option for patients whose tumours have BRAF alterations. The companion diagnostic is approved for use by qualified healthcare professionals across hospitals and clinical laboratories. As a kit-based solution, it can be implemented directly within hospitals and health systems, expanding testing access whilst enabling organisations to retain samples for future clinical research.
Labcorp expands access to FDA-approved PTEN diagnostic test for prostate cancer. 6 Aug 2026 Labcorp (NC, USA) has announced US-wide availability of the VENTANA PTEN (SP218) RxDx Assay, Roche's immunohistochemistry (IHC) companion diagnostic test for prostate cancer, marking a significant step forward in precision oncology. With the American Cancer Society (GA, USA) estimating >330,000 new cases of prostate cancer in 2026 in the United States, there is an urgent need for advanced diagnostic tools in this area. In recent years, focus has shifted to the tumor suppressor protein PTEN (phosphatase and tensin homolog on chromosome 10), which has been shown to play a critical role in regulating cell growth. Loss of PTEN protein expression has been linked with more aggressive disease progression and reduced benefit from current standard-of-care therapies in prostate cancer patients. You may also be interested in: The VENTANA PTEN (SP218) RxDx Assay is the first IHC companion diagnostic test approved by the US FDA for determining PTEN protein loss in the tumors of patients with prostate adenocarcinoma. The assay equips clinicians with critical biomarker information to help steer treatment decisions and support personalized patient care. "Biomarker testing is essential to advancing precision oncology and helping connect patients with the therapies most appropriate for their disease," commented Shakti Ramkissoon, Vice President and Medical Lead for oncology at Labcorp. "The launch of the VENTANA PTEN (SP218) RxDx Assay underscores how Labcorp is expanding access to innovative companion diagnostics and delivering the timely insights physicians need to make personalized treatment decisions." The assay facilitates the identification of patients who could be eligible for treatment with TRUQAP(R)(capivasertib), developed by AstraZeneca (Cambridge, UK). Now available through Labcorp's network of US-based laboratories, the assay complements the company's comprehensive portfolio of testing services supporting precision oncology care.
Labcorp has launched nationwide availability of Roche's VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic test for prostate cancer. The assay detects PTEN protein loss in prostate adenocarcinoma tumors, helping identify patients eligible for treatment with AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone acetate and prednisone. PTEN is a tumor suppressor protein that regulates cell growth. Loss of PTEN protein expression has been associated with more aggressive disease progression and reduced benefit from standard therapies. Labcorp participated in Roche's early access programme to support Day 1 laboratory readiness for the assay. The test is now available through Labcorp's national network of laboratories and complements the company's comprehensive portfolio of genomic and molecular testing services supporting precision oncology care.
Labcorp reported second quarter 2026 revenue of $3.73 billion, up 5.8% from the prior year period, and diluted earnings per share of $3.64, up 28.5%. Adjusted EPS rose 14.9% to $4.99. The company raised its full-year revenue growth guidance to 5.4% to 6.3%, up 30 basis points at the midpoint. Adjusted EPS guidance increased by 30 cents at the midpoint to a range of $18.10 to $18.55. Labcorp announced a $1.0 billion increase in its share repurchase authorisation, bringing total remaining authorisation to $1.4 billion. During the quarter, the company repurchased $353.8 million of stock and paid $58.7 million in dividends. The company expanded its oncology offerings and launched Marker by Labcorp, a genetic health panel for consumers.